Our study reinforces ATRX mutations as a marker of poor prognosis in leiomyosarcoma, aligning with prior observations in other sarcoma subtypes and extending this association to both uterine and non-uterine disease in a leiomyosarcoma-specific cohort [22,23,24]. Here, ATRX is linked to sarcoma.